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The T-box transcription factor, TBX3, is overexpressed in several cancers and has been proposed as a
chemotherapeutic target. Several lines of evidence suggest that TBX3 may be a key contributor to malignant
melanoma, a highly aggressive and intractable disease. Using in vitro and in vivo assays we demonstrate here for
the first time that overexpressing TBX3 in non-tumourigenic early stage melanoma cells is sufficient to promote
tumour formation and invasion. Furthermore, we show that TBX3 may play an important role as a reciprocal switch
between substrate dependent cell proliferation and tumour invasion.
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Background
Malignant melanoma is a highly aggressive and intractable
disease which has a rising incidence surpassing all other
cancers [1]. It is therefore imperative to identify new
targets for the development of improved therapies to treat
melanoma. To this end, an understanding of the molecu-
lar mechanisms underpinning the stepwise progression of
melanocytes to metastatic melanoma is important. Indeed,
in the last decade, several transcription factors have been
identified as potential therapeutic targets including MITF,
PAX3, SNAIL and the developmentally important T-box
transcription factor TBX3 [2-4].
TBX3 is overexpressed in a number of cancers inclu-
ding a subset of melanomas but its precise role in the
progression of this disease still needs to be clarified.
Earlier studies pointed to TBX3 contributing to the
oncogenic process by functioning as an anti-senescence
factor by directly repressing the negative cell cycle regu-
lator p19/p14ARF [5,6]. More recent studies however
suggest that TBX3 may function in advanced stages of
melanoma. Hoek and colleagues demonstrated that
TBX3 was upregulated in approximately 55% of cell lines
obtained from advanced melanoma lesions [7]. Further-
more, we have shown that knocking down TBX3 in
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distribution, and reproduction in any mediumcells inhibits cell migration and tumour formation [8]
and TBX3 was demonstrated to repress the E-cadherin
gene which is characteristically downregulated in VGP
melanoma [9]. Furthermore, Boyd and co-workers dem-
onstrated that oncogenic B-RAF is able to upregulate
TBX3 expression which in turn represses E-cadherin
levels [10].Findings
WM1650-TBX3 cells have decreased proliferative ability
To determine if TBX3 is not only essential but suf-
ficient to promote melanoma formation, we stably
transfected the non-tumourigenic human WM1650
radial growth phase (RGP) melanoma cell line, which
expresses undetectable levels of TBX3, with the pEGFP-
N3 vector in which the cytomegalovirus promoter drives
the expression of a green fluorescent protein tagged hu-
man TBX3.
Western blot and qRT-PCR analyses confirmed that
TBX3 was successfully overexpressed in the WM1650-
TBX3 cell line established (Figure 1a, b).
We previously reported that VGP and metastatic
melanoma cells in which TBX3 was depleted maintained
a higher proliferative ability than their control cells [8].
It was therefore hypothesised that the overexpression of
TBX3 in RGP cells would lead to a decrease in their
proliferative ability.
Indeed growth curves and pulsing the cells with 5-
bromo-2-deoxyuridine (BrdU), a synthetic thymidinetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 WM1650-TBX3 cells have decreased proliferative ability. (a) Real-time PCR (each data point represents the mean ± SD from at least
three independent experiments (*p < 0.05)) and (b) western blot (representative of three different experiments) analyses of TBX3 mRNA and
protein levels respectively in WM1650-ctrl and WM1650-TBX3 cells. p38 was used as a loading control. (c) Growth curve assays of cells grown in
medium supplemented with 10% or 2% FBS. Each data point represents the mean ± SD from at least three independent experiments (*p < 0.05)
(d) 5-bromo-2-deoxyuridine (BrdU) incorporation assay. Graph shows an average of BrdU-positive cells expressed as a percentage of total cells
counted at 1 hr and 8 hrs in 20 fields of view (*p < 0.05, mean +/− SD). (e) Cell cycle distribution was determined by staining cells with
propidium iodide and measuring their DNA content by flow cytometry. Percentage of cells in each phase of the cell cycle are shown in the
graph below (*p < 0.05, mean +/− SD). (f) Western blotting (representative of three different experiments) of the indicated proteins in WM1650-
ctrl and WM1650-TBX3 cells. The expression of TBX2, p53, p21, p16 and p14 was quantified as the densitometry value (pooled from three
different experiments) analysed by UN-SCAN-IT gel 6.1 software and was normalised to p38 levels as shown in the tables below.
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Figure 2 (See legend on next page.)
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Figure 2 WM1650-TBX3 cells have increased anchorage independence and migratory ability. Cell growth (a) in a 1% agar slurry and
visualised with p-iodonitrotetrazolium chloride stain and (b) in 0.8% methylcellulose and assessed by the MTT assay. Each data point represents
the mean ± SD from at least three independent experiments (*p < 0.05; **p < 0.0009). (c,d) Migratory ability of the WM1650-TBX3 and WM1650-
ctrl cells was compared using (c) in vitro scratch and (d) transwell motility assays. Each data point represents the mean ± SD from at least three
independent experiments (*p < 0.05). (e) Real-time PCR analysis (left panel, each data point represents the mean ± SD from at least three
independent experiments (*p < 0.05)) and western blotting (right panel; representative of three different experiments) of TBX3 and E-cadherin
expression in WM1650-ctrl and WM1650-TBX3 cells. The expression of E-cadherin was quantified as the densitometry value (pooled from three
different experiments) analysed by UN-SCAN-IT gel 6.1 software and was normalised to p38 levels as shown in the table below. (f) WM1650-TBX3
or WM1650-ctrl cells were injected subcutaneously into the flanks of 6 nude mice (3 males and 3 females for each cell line) and 29 days post-
injection, mice were euthanized, photographed and tumours excised for histological analyses. (g) Representative tumour section stained with
haematoxylin and eosin and photographed at 20× magnification. Black arrows show tumour cells invading skeletal muscle.
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further explore the reason(s) for the decrease in cell
proliferation, the cell cycle profile of WM1650-TBX3
and WM1650-ctrl cells were compared by flow cy-
tometry. The results showed that there were 10%
more WM1650-TBX3 cells in the G1 phase, but
10.5% fewer in the S-phase (Figure 1e). Furthermore,
while the WM1650-TBX3 cells had reduced levels of
p21, p16 and TBX2, they had increased levels of the
tumour suppressor proteins, p53 and p14 (Figure 1f ).
This is significant because TBX2, a homologue of
TBX3, was shown to be a powerful pro-proliferative
factor in melanoma and breast cancer cell lines
which express both TBX2 and TBX3 [8,11] and there
has been an indication that TBX2 and TBX3 can re-
press each other [9]. Together these results show
that TBX3 impacts negatively on melanoma cell
proliferation.
WM1650-TBX3 cells have increased anchorage
independence and migratory ability
To further explore the possibility that TBX3 may drive
RGP cells to a more aggressive melanoma phenotype
the anchorage independent growth and colony forming
ability of the WM1650-ctrl and WM1650-TBX3 cells
were analysed using soft agar and methyl cellulose cell
viability methylthiazol tetrazolium (MTT) assays. The
results show that TBX3 promoted anchorage indepen-
dent growth since the WM1650-TBX3 cells formed
more and larger colonies (Figure 2a, b). Similarly, the
two-dimensional scratch (Figure 2c) and transwell
motility (Figure 2d) assays showed that the WM1650-
TBX3 cells migrated significantly faster than the
WM1650-ctrl cells. To confirm that the mechanism by
which TBX3 affects melanoma cell adhesion and migra-
tion is through repressing E-cadherin, we investigated
the levels of this cell adhesion molecule. Our results
show that, compared to WM1650-ctrl cells, WM1650-
TBX3 cells had lower levels of E-cadherin mRNA and
protein (Figure 2e). To confirm the above findings
in vivo, the tumour forming ability of WM1650-TBX3and WM1650-ctrl cells was compared in nude mice.
While 100% of mice injected with WM1650-TBX3 cells
formed tumours ranging from 8 to 17.84 mm in
diameter, 0% of mice injected with WM1650-ctrl cells
formed tumours (Figure 2f ). The ability of TBX3 to
drive non-tumourigenic cells to form tumours is shown
to be highly sensitive and specific (100% in both cases).
H & E staining of tumour sections confirmed evidence
of tumour cell infiltration into the skeletal muscle of
the hind limb of mice injected with WM1650-TBX3
cells (Figure 2g black arrows).
Conclusion
This study demonstrates for the first time that increased
levels of TBX3 are sufficient to promote tumour forma-
tion and invasion of non-tumourigenic melanoma cells
in vivo. We hypothesise that this occurs as a result of
TBX3 repressing E-cadherin which leads to anchorage-
independent growth and migration. Furthermore, we
show that TBX3 may play an important role as a recipro-
cal switch between substrate dependent cell proliferation
and tumour invasion.
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